Beyond the blister: cannabinoids for pain in epidermolysis bullosa
Beyond the blister: cannabinoids for pain in epidermolysis bullosa
Epidermolysis bullosa (EB) is a rare inherited skin disease causing chronic blistering, open wounds, and lifelong multi-system complications. Among all the burdens of living with EB, pain stands out as the most debilitating, yet it remains severely undertreated. In his thesis, Nicholas Schräder, characterises the nature of EB pain and builds a scientific foundation for cannabinoid-based medicines (CBMs) as a promising treatment option.
Patient surveys established that pain is EB’s most pervasive unmet need, touching every aspect of quality of life. Detailed pain profiling revealed that EB pain is far more than wound-related: it carries strong neuropathic features, including burning, stabbing, and electric shock-like sensations, and shows signs of central sensitisation, where the nervous system itself becomes hypersensitive. This explains why pain can feel overwhelming even on relatively good skin days, and why standard painkillers so often fall short.
Three clinical case reports demonstrated meaningful benefits from sublingual THC/CBD oil (Transvamix), including reductions in pain, itch, and opioid use. An international survey of 71 patients from five continents reinforced these findings: 94% reported pain improvement, and 79% had reduced or stopped other pain medications entirely.
A randomised controlled trial confirmed clinically meaningful signals: 75% of participants achieved significant pain reduction with CBMs versus 50% with placebo. Strikingly, four participants using analgesic medications at baseline discontinued them during the CBM phase; none did so during placebo.
CBMs represent a promising and well-tolerated addition to EB pain management. Larger trials are now the essential next step.